Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
1. A peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt thereof, comprising an amino acid sequence consisting of Formula (Xa):
X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20 (Xa),
or a pharmaceutically acceptable salt thereof,
wherein
X1 is any amino acid or absent;
X2 is any amino acid or absent;
X3 is any amino acid or absent;
X4 is Abu;
X5 is Gln;
X6 is Thr;
X7 is Trp;
X8 is Gln;
X9 is Cys;
X10 is Phe, Tyr, a Phe analog, or a Tyr analog;
X11 is 1-Nal, 2-Nal, Phe(3,4-dimethoxy), or Phe(3,4-Cl 2 );
X12 is α-Me-Lys, α-Me-Leu, α-Me-Ser, α-Me-Val, Achc, Acvc, Acpc, Acbc, Aib, or 4-amino-4-carboxy-tetrahydropyran;
X13 is any amino acid;
X14 is any amino acid;
X15 is any amino acid,
X16 is any amino acid or absent;
X17 is any amino acid or absent;
X18 is any amino acid or absent;
X19 is any amino acid or absent; and
X20 is any amino acid or absent,
wherein the peptide inhibitor is cyclized via a thioether bond between X4 and X9, and
wherein 1-Nal is L-1-napthylalanine, 2-Nal is L-2-napthylalanine, Abu is 2-aminobutyric acid, α-Me-Lys is alpha-methyl-L-Lysine, α-Me-Leu is alpha-methyl-L-Leucine, α-Me-Ser is alpha-methyl-L-Serine, α-Me-Val is alpha-methyl-L-Valine, Ache is 1-aminocyclohexanecarboxylic acid, Acvc is 1-aminocyclopentanecarboxylic acid, Acpc is 1-aminocyclopropylcarboxylic acid, Acbc is 1-aminocyclobutanecarboxylic acid, and Aib is 2-aminoisobutyric acid.
2. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1 , wherein the peptide inhibitor comprises an N-terminal Ac group and a C-terminal NH 2 group.
3. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1 , wherein X3 is selected from Glu, (D)Glu, Arg, (D)Arg, Phe, (D)Phe, 2-Nal, Thr, Leu, or (D)Gln.
4. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1 , wherein X10 is Phe(4-OMe), Phe(4-CONH 2 ), or Phe[4-(2-aminoethoxy)].
5. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1 , wherein X11 is 2-Nal.
6. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1 , wherein the peptide inhibitor or pharmaceutically acceptable salt thereof is: Ac-[Abu]-QTWQCY-[2-Nal]-[α-Me-Lys]-ENG-NH 2 (SEQ ID NO:704) or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor is cyclized via a thioether bond between Abu and C.
7. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 3 , wherein the peptide inhibitor or pharmaceutically acceptable salt thereof is: Ac-[Abu]-QTWQC-[Phe(4-OMe)]-[2-Nal]-[α-Me-Lys]-ENG-NH 2 (SEQ ID NO:702) or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor is cyclized via a thioether bond between Abu and C.
8. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 3 , wherein the peptide inhibitor or pharmaceutically acceptable salt thereof is: Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]-W-[α-Me-Lys]-ENG-NH 2 (SEQ ID NO:782) or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor is cyclized via a thioether bond between Abu and C.
9. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 3 , wherein the peptide inhibitor or pharmaceutically acceptable salt thereof is: Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[α-Me-Lys]-[Lys(isovaleric acid)]-NG-NH 2 (SEQ ID NO:861) or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor is cyclized via a thioether bond between Abu and C.
10. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 3 , wherein the peptide inhibitor or pharmaceutically acceptable salt thereof is: Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[Aib]-QNG-NH 2 (SEQ ID NO:877) or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor is cyclized via a thioether bond between Abu and C.
11. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 3 , wherein the peptide inhibitor or pharmaceutically acceptable salt thereof is: Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[Aib]-[Lys(Ac)]-NA-NH 2 (SEQ ID NO:880) or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor is cyclized via a thioether bond between Abu and C.
12. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 3 , wherein the peptide inhibitor or pharmaceutically acceptable salt thereof is: Ac-[Abu]-QTWQC-[Phe[4-(2-(acetyl-aminoethoxy)]]-[2-Nal]-[α-Me-Lys(Ac)]-[Lys(Ac)]-NG-NH 2 (SEQ ID NO:900) or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor is cyclized via a thioether bond between Abu and C.
13. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 3 , wherein the peptide inhibitor or pharmaceutically acceptable salt thereof is: Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[α-Me-Lys]-ENQ-NH 2 (SEQ ID NO:911) or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor is cyclized via a thioether bond between Abu and C.
14. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 3 , wherein the peptide inhibitor or pharmaceutically acceptable salt thereof is: Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[α-Me-Lys]-ENN-NH 2 (SEQ ID NO:912) or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor is cyclized via a thioether bond between Abu and C.
15. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 3 , wherein the peptide inhibitor or pharmaceutically acceptable salt thereof is: Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[α-MeVal]-[Lys(Ac)]-NG-NH 2 (SEQ ID NO:915) or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor is cyclized via a thioether bond between Abu and C.
16. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 3 , wherein the peptide inhibitor or pharmaceutically acceptable salt thereof is: Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[α-Me-Leu)-[Cit]-NN-NH 2 (SEQ ID NO:954) or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor is cyclized via a thioether bond between Abu and C.
17. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 3 , wherein the peptide inhibitor or pharmaceutically acceptable salt thereof is: Ac—[(D)Phe]-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[α-Me-Lys]-ENN-NH 2 (SEQ ID NO:970) or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor is cyclized via a thioether bond between Abu and C.
18. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 3 , wherein the peptide inhibitor or pharmaceutically acceptable salt thereof is: Ac-T-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[α-Me-Lys]-ENN-NH 2 (SEQ ID NO:972) or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor is cyclized via a thioether bond between Abu and C.
19. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 3 , wherein the peptide inhibitor or pharmaceutically acceptable salt thereof is: Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[acbc]-ENN-NH 2 (SEQ ID NO:976) or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor is cyclized via a thioether bond between Abu and C.
20. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 3 , wherein the peptide inhibitor or pharmaceutically acceptable salt thereof is: Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[acpc]-ENN-NH 2 (SEQ ID NO: 1043) or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor is cyclized via a thioether bond between Abu and C.
21. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 3 , wherein the peptide inhibitor or pharmaceutically acceptable salt thereof is: Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[achc]-ENN-NH 2 (SEQ ID NO: 1047) or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor is cyclized via a thioether bond between Abu and C.
22. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 3 , wherein the peptide inhibitor or pharmaceutically acceptable salt thereof is: Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[4-amino-4-carboxy-tetrahydropyran]-ENN-NH 2 (SEQ ID NO:980) or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor is cyclized via a thioether bond between Abu and C.
23. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 3 , wherein the peptide inhibitor or pharmaceutically acceptable salt thereof is: Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[alpha-methyl-L-Leucine]-QN-[betaAla]-NH 2 (SEQ ID NO:984) or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor is cyclized via a thioether bond between Abu and C.
24. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 3 , wherein the peptide inhibitor or pharmaceutically acceptable salt thereof is: Ac-(D)Phe-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[4-amino-4-carboxy-tetrahydropyran]-ENN-NH 2 (SEQ ID NO:992) or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor is cyclized via a thioether bond between Abu and C.
25. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 3 , wherein the peptide inhibitor or pharmaceutically acceptable salt thereof is: Ac—[(D)Arg]-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[4-amino-4-carboxy-tetrahydropyran]-ENN-NH 2 (SEQ ID NO:993) or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor is cyclized via a thioether bond between Abu and C.
26. A pharmaceutical composition comprising the peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1 .